Lipid flippase dysfunction as a novel therapeutic target for endosomal anomalies in Alzheimer’s disease
Nanaka Kaneshiro(University of California, Riverside), Nobumasa Takasugi(Okayama University), Takashi Uehara(Okayama University), Tadafumi Hashimoto(Kyushu University), Masato Komai(Okayama University), Takashi Sakurai(Juntendo University), Atsuya Ikeda(Okayama University), Takeshi Iwatsubo(National Center of Neurology and Psychiatry), Yuji Kamikubo(Juntendo University), Ryosuke Imaoka(Okayama University)
Cited by 0
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Lecanemab in Early Alzheimer’s Disease
|New England Journal of Medicine|2022|5k
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
|Journal of Neuropathology & Experimental Neurology|2012|2.1k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k
Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
|Proceedings of the National Academy of Sciences|2009|844